Jun. 10 at 2:53 PM
$SGMO $BMRN unfortunately I put my eggs in the Sangamo basket. I thought the Fabry data was going to be strong enough for BP to come along and hop on board.
Then BioMarin purchased Amicus for 4.8B all cash.. " With the acquisition, BioMarin adds two new treatments for lysosomal storage diseases, Galafold (migalastat) for Fabry disease..." Im not a scientist, but biomarin bought this for a reason.. currently on the market, brings in money today. Although the acquisition was likely a BOD pleaser. Still, its a treatment for Fabry.
Once this occurred, I wondered why we cant find a mediocre deal? Biomarin was likely giving out retention bonuses to keep employees from heading to Sangamo as they both were racing to get Hemophila therapies to market.. seemed like guaranteed blockbuster treatments.
Fast forwarding.... Hemophila turns into a disaster for both companies. Pfeizer abandons ship. BioMarin sells distribution rights to Roctavian (Hemophila).
Here I am, expecting the worst. GL to us
